Treatment of ANCA-associated vasculitis [2]

JAMA

Volumn 298, Issue 23, 2007, Pages 2739-2740

  Wise, Matt P ^a   Frost, Paul ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; OKT 4; PREDNISOLONE; THYMOCYTE ANTIBODY; CD4 ANTIGEN; CD52 ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; TUMOR ANTIGEN;

HUMAN; IMMUNOTHERAPY; LETTER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; VASCULITIS; WEGENER GRANULOMATOSIS; IMMUNOLOGY; NOTE;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD4; ANTIGENS, NEOPLASM; GLYCOPROTEINS; HUMANS; VASCULITIS;

EID: 37349009031     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.23.2739-b     Document Type: Letter

References (5)

1. Bosch X, Guilabert A, Espinosa G, Mirapeix E. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: a systematic review. JAMA. 2007;298(6):655-669.
2. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488-498.
3. Lockwood CM, Thiru S, Stewart S, et al. Treatment of refractory Wegener's granulomatosis with humanised monoclonal antibodies. QJM. 1996;89(12):903-912.
4. Lockwood CM. Refractory Wegener's granulomatosis: a model for shorter immunotherapy of autoimmune diseases. J R Coll Physicians Lond. 1998;32(5):473-478.
5. Isaacs JD. T cell immunomodulation - the Holy Grail of therapeutic tolerance. Curr Opin Pharmacol. 2007;7(4):418-425.